Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Sutro Biopharma, Inc. (STRO) had Income from Continuous Operations of $-11.50M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$63.74M |
|
$-11.50M |
|
-- |
|
$63.74M |
|
$67.09M |
|
$-3.35M |
|
$-8.17M |
|
$-11.52M |
|
$-11.52M |
|
$-11.50M |
|
|
Income from Continuous Operations |
$-11.50M |
$-11.50M |
|
$-11.50M |
|
$-3.35M |
|
$-2.48M |
|
84.58M |
|
84.58M |
|
$-0.14 |
|
$-0.14 |
|
| Balance Sheet Financials | |
$231.63M |
|
$14.98M |
|
$30.73M |
|
$262.36M |
|
$74.25M |
|
-- |
|
$220.22M |
|
$294.47M |
|
$-32.11M |
|
$-32.11M |
|
$-32.11M |
|
84.72M |
|
| Cash Flow Statement Financials | |
$-112.61M |
|
$-13.68M |
|
$0.01M |
|
$191.16M |
|
$64.88M |
|
$-126.28M |
|
$10.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.12 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-5.25% |
|
-5.25% |
|
-- |
|
-18.07% |
|
-18.04% |
|
$-113.87M |
|
-- |
|
-- |
|
-- |
|
0.24 |
|
-- |
|
7.97 |
|
11.29 |
|
35.81% |
|
35.81% |
|
-4.38% |
|
35.81% |
|
$-0.38 |
|
$-1.35 |
|
$-1.33 |
|